Rekvina Laboratories held its Extra-Ordinary General Meeting on April 10, 2026, to seek shareholder approval for six key resolutions.
Members approved an increase in the company's authorized share capital and alterations to its Memorandum and Articles of Association.
Resolutions passed included approvals for investments beyond normal limits, related party transactions, and two separate preferential share issuances.
All 17 members present voted via polling paper under the supervision of a scrutinizer, and the meeting concluded in 20 minutes.